However, PD1/PD-L1 inhibitors, in combination with chemotherapy, radiotherapy, targeted drug therapy, and other immunotherapies, are capable of increasing CD8+ T cell number in the patient's tumor microenvironment, disrupting tumor immune escape, and enhancing the antitumor effect of PD1/PD-L1 inhibitors [18, 21]. This evidence concerns the gene CD8A and neoplasm.